What Does CME Accreditation Stand for?

References

• Consensus statement for independence and funding of CME/CPD. [cited 2020 Jun 1]. Available from: https://academy4cpdaccreditation.files.wordpress.com/2018/11/consensus-statement-for-independence-and-funding-of-cme_cpd_final_sept-en1.pdf
   Google Scholar
• Gehle HA, Herrmann H. Criteria to assess independence of continuing medical education (CME)- Independence through competence and transparency. J Eur CME. 2020;9:1. DOI:10.1080/21614083.2020.1811557.
   Google Scholar
• World medical association declaration of seoul on professional autonomy and independence. [cited 2020 Jun 1]. Available from: https://www.wma.net/policies-post/wma-declaration-of-seoul-on-professional-autonomy-and-clinical-independence/
   Google Scholar
• World medical association declaration of geneva. [cited 2020 Jun 1]. Available from: https://www.wma.net/policies-post/wma-declaration-of-geneva/
   Google Scholar
• Densen P. Challenges and opportunities facing medical education. Trans Am Clin Climatol Assoc. 2011;122:48–4.
   PubMedGoogle Scholar
• Kann B, Johnson SB, Aerts HJWL, et al. Changes in length and complexity of clinical practice guidelines. Oncology. 1996–2016. DOI:10.1001/jamanetworkopen.2020.0841.
   Google Scholar
• Court of justice upholds EMA’s approach to transparency. [cited 2020 Jun 1]. Available from: https://www.ema.europa.eu/en/documents/press-release/court-justice-upholds-emas-approach-transparency_en.pdf
   Google Scholar
• Köhler M, Haag S, Biester K, et al. Information on new drugs at market entry: retrospective analysis of health technology assessment reports versus regulatory reports, journal publications, and registry reports. BMJ. 2015;350:h796.
   Web of Science ®Google Scholar
• Available from: https://www.iqwig.de/en/press/press-releases/all-clinical-trial-data-on-covid-19-medicines-and-vaccines-should-be-published-on-the-day-of-marketing-authorisation.13015.html
   Google Scholar
• Available from: https://www.fda.gov/news-events/fda-voices/insight-fdas-revised-policy-antibody-tests-prioritizing-access-and-accuracy
   Google Scholar
• Zarin DA. The culture of trial results reporting at academic centers. JAMA Internal Medicine. 180(2):319–320.  DOI: 10.1001/jamainternmed.2019.4200
   Google Scholar
• Drazen JM. Believe the data. N Engl J Med. 2012;367(12):1152–1153.
   Web of Science ®Google Scholar
• Kesselheim AS, Robertson CT, Myers JA, et al. A randomized study of how physicians interpret research funding disclosures. N Eng J Med. 2012;367:1119–1127.
   PubMed Web of Science ®Google Scholar
• Dal Ré R, Kesselheim AS, Bourgeois FT. Increasing access to FDA inspection reports on irregularities and misconduct in clinical trials. JAMA. 2020;323:1903–1904.  doi: 10.1001/jama.2020.1631.
   Google Scholar
• Zhai M, Lye CT, Kesselheim AS. Need for transparency and reliable evidence in emergency use authorizations for coronavirus disease 2019 (COVID-19) therapies. JAMA Intern Med. 2020;180(9):1145.
   Web of Science ®Google Scholar
• Available from: https://www.washingtonpost.com/health/2020/05/04/fda-steps-up-scrutiny-coronavirus-antibody-tests-ensure-accuracy/
   Google Scholar
• Mahase E. Covid-19: antibody test that claims to be 99% accurate is certified by EU. BMJ. 2020;369:m1742.
   Google Scholar
• Mahase E. Covid-19: “Unacceptable” that antibody test claims cannot be scrutinized, say experts. BMJ. 2020;369:m2000.
   Google Scholar
• Mahase E. Covid-19: two antibody tests are highly specific but vary in sensitivity, evaluations find. BMJ. 2020;369:m2066.
   Google Scholar
• Zagury-Orly I, Schwartzstein RM. Covid-19- A reminder to reason. N Engl J Med. 2020; 383:e12. DOI:10.1056/NEJMp2009405.
   Google Scholar
• https://www.ksta.de/koeln/-durchbruch-fuer-risikogruppe–wird-aus-remdesivir-eine-alternative-zum-impfstoff–36742410
   Google Scholar
• Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of Covid-19- preliminary report. N Engl J Med. DOI:10.1056/NEJMoa2007764.
   Google Scholar
• Mahase E. Covid-19: remdesivir is helpful but not a wonder drug, say researchers. BMJ. 2020;369:m1798.
   Google Scholar
• Evans SJW, Mills P, Dawson J. The end of the p-value? Br Heart J. 1988;60:177–180.
   Google Scholar
• Harrington D, D’Agostino RB, Gatsonis C, et al. New guidelines for statistical reporting. J N Engl J Med. 2019;381(3):285–286.
   Web of Science ®Google Scholar
• Weinfurt KP. Clarifying the meaning of clinically meaningful benefit in clinical research. JAMA. 2019;322(24):2381–2382. DOI:10.1001/jama.2019.18496.
   Google Scholar
• Braithwaite RS. EBM’s six dangerous words. JAMA. 2020;323(17):1676–1677.
   Web of Science ®Google Scholar
• Smith PRM, Ware L, Adams C, et al. Claims of “no difference” or “no effect” in Cochrane and other systematic reviews. BMJ Evid Based Med. DOI:10.1136/bmjebm-2019-111257
   Google Scholar
• Corneli A, Calvert SB, Powers III, et al. Consensus on language for advance informed consent in health care-associated pneumonia clinical trials using a Delphi process. JAMA Network Open. 2020;3(5):e205435.
   Web of Science ®Google Scholar
• Khan MS, Lateef N, Siddiqi TJ, et al. Level and prevalence of spin in cardiovascular clinical trial reports with statistically nonsignificant primary outcomes. JAMA Network Open. 2019;2(5):e192622.
   PubMed Web of Science ®Google Scholar
• Rubinstein SM, Sigworth EA, Etemad S, et al. indication of measures of uncertainty for statistical significance in abstracts of published oncology trials. JAMA Network Open. 2019;2(12):e1917530.
   Web of Science ®Google Scholar
• Lundh A, Lexchin J, Mintzes B et al. Industry sponsorship and research outcomes (Review). [cited 2020 Jun 1]. Available from: https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.MR000033.pub3/epdf/full
   Google Scholar
• Nast A, Sporbeck B, Jacobs A, et al. Perception of the binding nature of guideline recommendations. Ger Arztebl Int. 2013;110:663–668.
   Web of Science ®Google Scholar
• Weberschock T, Dreher A, Follmann M, et al. Bindingness of recommendations in guidelines: survey on perception among guideline developers. ZEFQ. 2016;113:1–8.
   Google Scholar
• Vaduganathan M, van Meijgaard J, Mehra MR, et al. Prescription fill patterns for commonly used drugs during the Covid-19 pandemic in the USA. JAMA. 2020; 323(24): 2524–2526.
   Google Scholar
• Magagnioli J, Narendran S, Pereira F et al. Outcomes of hydroxychloroquine usage in USA veterans hospitalized with Covid-19 medRxiv preprint doi: 10.1101/2020.04.16.20065920
   Google Scholar
• Kim MS, Prasad V. The clinical trials portfolio for on-label and off-label studies of eculizumab. JAMA Intern Med. 2019. DOI:10.1001/jamainternmed.2019.4694
   Web of Science ®Google Scholar
• Fanaroff AC, Califf RM, Windecker S, et al. Levels of evidence supporting american college of cardiology/American Heart Association and European society of cardiology guidelines, 2008-2018. JAMA. 2019;321(11):1069–1080. .
   Web of Science ®Google Scholar
• Guinart G, Kane JM, Corell CU. Is transcultural psychiatry possible? JAMA. 2019;322(22):2167–2168.
   Web of Science ®Google Scholar
• Weiss W. A “sleeper” effect in opinion change. J Abnormal Soc Psychol. 1953;48(2):173–180.
   Web of Science ®Google Scholar
• Cook J, Lewandowsky S. The debunking handbook. St. Lucia, Australia: university of Queensland; 2011. November 5. ISBN 978-0-646-56812-6. Available from: http://sks.to/debunk
   Google Scholar
• Rasmussen K, Bero L, Redberg R, et al. Collaboration between academics and industry in clinical trials: cross sectional study of publications and survey of lead academic authors. BMJ. 2018;363:k3654.
   PubMedGoogle Scholar
• Wouters OJ. Lobbying expenditures and campaign contributions by the pharmaceutical and health product industry in the USA, 1999-2018. JAMA Intern Med. 2020;180(5):688–697.
   Web of Science ®Google Scholar
• Moynihan R, Bero L, Hill S, et al. Pathways to independence: towards producing and using trustworthy evidence. BMJ. 2019;367:l6576.
   Google Scholar